Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

(2019) Benjamin G. Barwick et al.   Nature Communications

Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma

(2019) Benjamin G. Barwick et al.   Frontiers in Immunology

MCL1 gene co-expression module stratifies multiple myeloma and predicts response to proteasome inhibitor-based therapy

(2018) Ayaz Ali Samo et al.   GENES CHROMOSOMES & CANCER

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

(2018) Brian A. Walker et al.   LEUKEMIA

Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis

(2018) Phaik Ju Teoh et al.   BLOOD

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

(2018) Aurore Perrot et al.   BLOOD

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

(2017) Brian G M Durie et al.   LANCET

Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation

(2017) Gunjan L. Shah et al.   LEUKEMIA & LYMPHOMA

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

(2017) Michel Attal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

(2015) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial

(2013) A. K. Stewart et al.   BLOOD

Gain(1)(q21) is an Unfavorable Genetic Prognostic Factor for Patients With Relapsed Multiple Myeloma Treated With Thalidomide but Not for Those Treated With Bortezomib

(2013) Jan Smetana et al.   Clinical Lymphoma Myeloma & Leukemia

Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value

(2013) G. An et al.   HAEMATOLOGICA

Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients

(2013) A K Nooka et al.   LEUKEMIA

Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients

(2013) B Hebraud et al.   LEUKEMIA

Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival

(2012) Hervé Avet-Loiseau et al.   JOURNAL OF CLINICAL ONCOLOGY

A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial

(2011) K D Boyd et al.   LEUKEMIA

A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value

(2010) B. A. Walker et al.   BLOOD

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

(2010) M A Dimopoulos et al.   LEUKEMIA

Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains

(2010) Hong Chang et al.   LEUKEMIA RESEARCH

Gain of 1q21 Is an Unfavorable Genetic Prognostic Factor for Multiple Myeloma Patients Treated with High-Dose Chemotherapy

(2009) Pavel Nemec et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma

(2009) H Chang et al.   BONE MARROW TRANSPLANTATION

Prognostic Significance of Copy-Number Alterations in Multiple Myeloma

(2009) Hervé Avet-Loiseau et al.   JOURNAL OF CLINICAL ONCOLOGY